Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30802795 | 0.83 | HRH3 (0.42) | HRH3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL3542933 | 0.80 | HTR1A (0.51) | HRH3CYP2A6 | |
| SCHEMBL3138137 | 0.77 | HRH3 (0.41) | HRH3HTR3ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL3546441 | 0.77 | KDM4E (0.40) | KDM4EALDH1A1MAPT | |
| SCHEMBL19582852 | 0.76 | HRH3 (0.47) | HRH3CYP2A6KDM4EMEN1ALDH1A1 | |
| SCHEMBL3541006 | 0.76 | CHRNB2 (0.45) | HRH3HTR3ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5465191 | 0.76 | HTR3A (0.54) | HRH3HTR3ASLC6A4SLC6A3 | |
| SCHEMBL3126701 | 0.76 | HTR3A (0.36) | HTR3AOPRM1OPRD1OPRK1 | |
| SCHEMBL3129265 | 0.76 | BRAF (0.37) | HTR3AMEN1MAPTKMT2AOPRM1 | |
| SCHEMBL3541104 | 0.76 | JAK1 (0.46) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704991-B2 | Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-27 | — | — | US | claimed |
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-11-13 | — | — | US | claimed |
| US-7704991-B2 | Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-27 | — | — | US | disclosed |
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-11-13 | — | — | US | disclosed |
| EP-1869050-A1 | NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106090-A1 | NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | HRH3 343/4885HTR3A 80/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.